Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Endonovo TherapeuticsENDV EV-to-FCF is 91.91 as of Jul. 14, 2026. Among 335 Biotechnology companies, Endonovo Therapeutics ranks worse than 87.46% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Endonovo Therapeutics's Enterprise Value is $7.08 Mil.
Endonovo Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was $0.08 Mil. Therefore, Endonovo Therapeutics's EV-to-FCF for today is 91.91.
The historical rank and industry rank for Endonovo Therapeutics's EV-to-FCF or its related term are showing as below:
ENDV'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 91.91
Current: 91.91
During the past 13 years, the highest EV-to-FCF of Endonovo Therapeutics was 91.91. The lowest was 0.00. And the median was 0.00.
ENDV's EV-to-FCF is ranked worse than 87.46% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs ENDV: 91.91
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Endonovo Therapeutics's PE Ratio (TTM) for today is calculated as:
Endonovo Therapeutics's share price for today is $0.0001.
Endonovo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Endonovo Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Endonovo Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Endonovo Therapeutics's EV-to-FCF falls into.
Endonovo Therapeutics's current Enterprise Value is $7.08 Mil.
Endonovo Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Endonovo Therapeutics (ENDV) has a EV-to-FCF of 91.91 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Endonovo Therapeutics and its competitors. According to the industry distribution chart, Endonovo Therapeutics ranks #293 out of 335 companies in the Biotechnology industry, placing it in the top 87.5%.
Is Endonovo Therapeutics' EV-to-FCF too high?
Endonovo Therapeutics' current EV-to-FCF is 91.91. The Biotechnology industry median EV-to-FCF is 15.34. Endonovo Therapeutics' value of 91.91 is 499.2% above this industry median. Based on the distribution chart, Endonovo Therapeutics ranks #293 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Endonovo Therapeutics' EV-to-FCF compare to RGBP and SIGY?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #293 out of 335 companies for EV-to-FCF. This places Endonovo Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.34. Endonovo Therapeutics' value of 91.91 is 499.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Endonovo Therapeutics's current EV-to-FCF of 91.91 is 499.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Endonovo Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Endonovo Therapeutics's current EV-to-FCF is 91.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current EV-to-FCF of 91.91. The current EV-to-FCF is 91.91 and 499.2% above the Biotechnology industry median of 15.34. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current EV-to-FCF is 91.91 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENDV has been successfully added to your 
